Burzynski Research Institute (BZYR) EBIT (2010 - 2025)
Burzynski Research Institute (BZYR) posted EBIT of -$328862.0 for Q4 2025, up 1.5% sequentially from -$333867.0 in Q3 2025, and up 6.64% YoY from -$308394.8 in Q4 2024.
Burzynski Research Institute (BZYR) EBIT (2010 - 2025) Analysis & Trends
Burzynski Research Institute has reported EBIT for 16 years, with the latest figure at -$328862.0 in Q4 2025.
- Quarterly EBIT rose 6.64% year-over-year to -$328862.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was -$1.3 million (up 11.63% YoY) and the FY2025 annual result came in at -$1.4 million, down 3.8% from the prior year.
- EBIT improved to -$328862.0 in Q4 2025 per BZYR's latest filing, from -$333867.0 in the prior quarter.
- Over five years, EBIT peaked at -$170879.0 in Q1 2022 and troughed at -$433015.0 in Q4 2023.
- A 5-year average of -$292985.1 and a median of -$290101.5 in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2023: EBIT jumped 31.9% in 2022, then slumped 71.4% in 2023.
- Over 5 years, EBIT stood at -$264776.0 in 2021, then gained by 4.58% to -$252639.0 in 2022, then plunged by 71.4% to -$433015.0 in 2023, then climbed by 18.65% to -$352239.0 in 2024, then climbed by 6.64% to -$328862.0 in 2025.
- According to Business Quant data, EBIT over the past three periods registered -$328862.0, -$333867.0, and -$331451.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | -328,862.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -328,862.00 |
| Aug 31, 2025 | -333,867.00 |
| May 31, 2025 | -331,451.00 |
| Feb 28, 2025 | -292,798.00 |
| Nov 30, 2024 | -352,239.00 |
| Aug 31, 2024 | -369,838.00 |
| May 31, 2024 | -371,332.00 |
| Feb 29, 2024 | -362,907.00 |
| Nov 30, 2023 | -433,015.00 |
| Aug 31, 2023 | -252,104.00 |
| May 31, 2023 | -287,405.00 |
| Feb 28, 2023 | -215,998.00 |
| Nov 30, 2022 | -252,639.00 |
| Aug 31, 2022 | -215,918.00 |
| May 31, 2022 | -231,737.00 |
| Feb 28, 2022 | -170,879.00 |
| Nov 30, 2021 | -264,776.00 |
| Aug 31, 2021 | -224,718.00 |
| May 31, 2021 | -316,283.00 |
| Feb 28, 2021 | -250,936.00 |